Pandemic Influenza Preparedness (PIP) Framework

What is the PIP Framework?

The PIP Framework brings together Member States, industry, other stakeholders and WHO to implement a global approach to pandemic influenza preparedness and response. Its key goals include: to improve and strengthen the sharing of influenza viruses with human pandemic potential; and to increase the access of developing countries to vaccines and other pandemic related supplies. The Framework was developed by Member States. It came into effect on 24 May 2011 when it was unanimously adopted by the Sixty-fourth World Health Assembly.

WHO/Jermias da Cruz. Partnership Contribution funded training in Infection Prevention Control, Timor Leste

Partnership Contribution High Level Implementation Plan II (HLIP II)

WHO strengthens countries’ capacities to prepare for the next influenza pandemic with the Partnership Contribution, an annual US$ 28 million contribution to WHO from influenza vaccine, pharmaceutical and diagnostic manufacturers that use the WHO GISRS. In 2013, WHO issued the first five-year, high-level Partnership Contribution Implementation Plan 2013-2016 (HLIP I). The second plan (2018-2023) will build on achievements and lessons learnt from implementing HLIP I. To learn more about the process to develop this plan and how you can get involved click on the following link.

WHO. Partnership Contribution funds support 5th joint WHO/Europe and ECDC Annual Influenza Surveillance Meeting

Partners have contributed US$125 million to improve pandemic preparedness capacity

25 July 2017 –To date, manufacturers have contributed over US$ 125 million to WHO under the WHO Partnership Contribution (PC). These funds have been used to improve laboratory and surveillance capacity, carry out burden of disease studies, improve risk communications, plan for deployment of pandemic products, and boost regulatory capacity. To learn more about how these funds have been used to improve pandemic preparedness see the following links.

WHO/Jermias da Cruz. Partnership Contribution funded training on influenza in Timor Leste

400 million doses of pandemic vaccine secured for next pandemic

25 July 2017 - WHO has concluded 11 SMTA2 benefit sharing agreements with vaccine and antiviral manufacturers. The commitments made under these agreements will provide real-time access by WHO to an estimated 400M doses of pandemic vaccine and 10M treatment courses of antivirals for use by countries in need during the next pandemic. WHO has also signed one agreement with a diagnostic manufacturer, securing 250K diagnostic kits use during the next pandemic.

WHO /Harold Ruiz. H1N1 response in Mexico

Virus Sharing

Influenza virus sharing, conducted by the WHO Global Influenza Surveillance and Response System (GISRS), is vital to global pandemic preparedness. The sharing of viruses facilitates pandemic risk assessment, the development of candidate vaccine viruses, updating of diagnostic reagents and test kits, and surveillance for resistance to antiviral medicines.

Partnership Contribution

The PIP Framework established a Benefit Sharing System that includes an annual Partnership Contribution (PC) to WHO from influenza vaccine, diagnostic and pharmaceutical manufacturers using the WHO Global Influenza Surveillance and Response System (GISRS).

Advisory Group

The Advisory Group (AG) is an independent group of 18 experts, which forms part of the oversight mechanism for the PIP Framework. It is responsible for monitoring implementation of the PIP Framework, and for providing evidence-based reporting, assessment and recommendations regarding its functioning.

Advisory Group work on Genetic Sequence Data

PIP Framework section 5.2.4 requests the Director-General to consult with the PIP Advisory Group on the best process for further discussion and resolution of issues related to the handling of the genetic sequence data (GSD) of influenza viruses with pandemic potential, under the Framework. For more information on the work of the PIP Advisory Group on GSD see the following link.

Standard Material Transfer Agreements 2 (SMTA2)

SMTAs 2 are legally-binding contracts between WHO and non-GISRS entities that receive PIP Biological Materials (PIP BM) from the Global Influenza Surveillance and Response System (GISRS). Through this contract, the entity commits to provide to WHO specific items that can be used to prepare for (e.g. training, technology license) or respond to (e.g. vaccines, antivirals, diagnostic kits) pandemic influenza

Implementation of Decision WHA70(10)

At the 70th World Health Assembly Member States considered the PIP Review Group Report and made a number of requests to the Director-General, these are contained in decision WHA70(10).

Analysis under paragraph 8(b)

Based on Member States’ request in decision WHA70(10), paragraph 8(b), the Director-General will conduct an Analysis to address two topics:

• The implications of pursuing or not pursuing possible approaches to include seasonal influenza viruses in the PIP Framework; and

• The implications of pursuing or not pursuing possible approaches to genetic sequence data under the PIP Framework.

Audit under paragraph 8(e)

Collaboration with SCBD and other international organizations

Decision WHA70(10), paragraph 8(f) requests the WHO Secretariat “to continue consultations with the Secretariat of the Convention on Biological Diversity and other relevant international organizations, as appropriate.” Information on these collaborations can be found at the following link: This page also contains the Secretariat’s study: Implementation of the Nagoya Protocol and Pathogen Sharing: Public Health Implications, which is available in all WHO official languages.

What's new


Postponed Consultation on the implementation of WHA70(10)8(b)
Click here for more information
[New!] Information Session
10 April 2018
PIP Advisory Group meeting
11-13 April 2018 (planned)

New Documents

Contact us

PIP Framework Secretariat